Research of Biomarkers in Parkinson Disease

Related Clinical Trial
Test-retest Study With [18F]PI-2620 in PSP-RS and NDC Evaluation of the Efficacy of a Two-week EMST on Dysphagia in Parkinsonian Patients Optimization of Morphomer-based Alpha-synuclein PET Tracers Evaluation of [18F]APN-1607 as a PET Biomarker A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY Complex Eye Movements in Parkinson’s Disease and Related Movement Disorders tDCS and Speech Therapy for Motor Speech Disorders Caused by FTLD Syndromes: a Feasibility Study Application od Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA) Remote Monitoring in Progressive Supranuclear Palsy (PSP) Trial of Parkinson’s And Zoledronic Acid Rho Kinase (ROCK) Inhibitor in Tauopathies – 1 UPenn Observational Research Repository on Neurodegenerative Disease Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies The MOTIVE-PSP Initiative A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy Efficacy and Safety of Transcranial dIrect Current stiMulation (tDCS) in Progressive Supranuclear Palsy (PSP) (STIM-PSP) Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy Misfolded Proteins in the Skin of People With Parkinson’s Disease and Other Parkinsonism Neurodegenerative Diseases Registry Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer’s Disease, Other Dementias and Normal Controls Brain Network Activation in Patients With Movement Disorders Neurologic Stem Cell Treatment Study ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes ADDIA Proof-of-Performance Clinical Study Defining Phenotypes of Movement Disorders :Parkinson’s Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography. Gait Analysis in Neurological Disease Diagnosing Frontotemporal Lobar Degeneration Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies Study of the Neural Basis of Analogical Reasoning Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Phase 1 Test-retest Evaluation of [18F]MNI-958 PET Diagnostic and Prognostic Biomarkers in Parkinson Disease Tau Imaging With JNJ067 Research of Biomarkers in Parkinson Disease More Than a Movement Disorder: Applying Palliative Care to Parkinson’s Disease Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism Identifying Biomarkers of Parkinson’s Disease Using Magnetic Resonance Imaging (MRI) Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) Davunetide (AL-108) in Predicted Tauopathies – Pilot Study Robot Walking Rehabilitation in Parkinson’s Disease Human CNS Tau Kinetics in Tauopathies 4-Repeat Tauopathy Neuroimaging Initiative – Cycle 2 In-Home Care for Patients With PSP and Related Disorders Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) Biomarkers in Parkinsonian Syndromes Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Effects of Coenzyme Q10 in PSP and CBD 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism Oxford Study of Quantification in Parkinsonism A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects The Neural Basis for Frontotemporal Degeneration Analysis of the Enteric Nervous System Using Colonic Biopsies Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy 4 Repeat Tauopathy Neuroimaging Initiative A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson’s Disease and Progressive Supranuclear Palsy. Safety Study of TPI-287 to Treat CBS and PSP Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Neuroprotection and Natural History in Parkinson’s Plus Syndromes (NNIPPS) Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy Pathophysiology of Gait and Posture in Progressive Supranuclear Palsy A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism tDCS Plus Physical Therapy for Progressive Supranuclear Palsy Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration Risk Factors for Progressive Supranuclear Palsy (PSP) Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy Neuropsychological Evaluation for Early Diagnosis of PSP Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer’s, Progressive Supranuclear Palsy Subjects, and Controls A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK The Study to Evaluate the Safety and Efficacy of Spinal Cord Stimulation on Progressive Supranuclear Palsy Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Young Plasma Transfusions for Progressive Supranuclear Palsy Study of BIIB092 in Participants With Progressive Supranuclear Palsy A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Deep TMS for the Treatment of Patients With Parkinson’s Disease and Progressive Supranuclear Palsy Rehabilitation in Patients With Progressive Supranuclear Palsy A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) Quality of Life of the Patient and the Burden of the Caregiver in Progressive Supranuclear Palsy An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP). Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine) Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy Postural Instability in Progressive Supranuclear Palsy

Brief Title

Research of Biomarkers in Parkinson Disease

Official Title

GENomic Biomarkers for PARKinson's Disease

Brief Summary

      The main goal of the GENEPARK consortium is to employ innovative haemogenomic approaches to
      determine gene expression profiles specific for genetic and idiopathic Parkinson's disease
      (PD) patients. These gene expression signatures will be utilised clinically as non-invasive
      diagnostic tests for PD. The sensitivity of the newly developed diagnostic test will be
      determined by extensive validations on an independent cohort of PD patients, whereas the
      specificity will be assessed by testing patients with atypical parkinsonisms, including
      multiple system atrophy, progressive supranuclear palsy and diffuse Lewy body disease. In
      order to test the specificity of the diagnostic set in other disorders that affect basal
      ganglia, Huntington's disease and dopa responsive dystonia patients will be analysed. The
      second objective of the proposal is to determine correlations between gene expression
      signatures and different stages of PD and thus provide the basis for early diagnosis and
      monitoring of disease progression. These changes in blood gene expression will be correlated
      with alterations detected by neuroimaging in the brain of PD patients. Such combinations of
      molecular and morphological markers of disease may ultimately facilitate the selection and
      monitoring of neuroprotective therapies for PD. Finally, GENEPARK aims to develop new
      bioinformatic software tools for selection of genomic biomarkers using microarray data. A set
      of established computational tools will be applied and novel methods, some of them based on
      mechanistic modelling of the neurodegenerative diseases, will be developed in order to study
      the advantages and limitations of the different methodologies.

      With special emphasis on the careful clinical selection of patients and sufficient power
      regarding patient numbers, as well as extensive quality control and validation of the data,
      GENEPARK aims to develop a standardised approach to development and validation of
      haemogenomic biomarkers of disease.
    

Detailed Description

      Employ innovative haemogenomic approaches to determine gene expression signatures specific
      for idiopathic Parkinson's disease (PD). There is currently no specific clinical or
      laboratory diagnostic test available for PD. In GENEPARK, blood samples from patients with
      genetic PD and idiopathic PD will be analysed by microarrays to identify gene expression
      signatures specific for PD. The specificity of the new biomarkers for PD will be tested by
      the analysis of patients with atypical parkinsonisms, including multiple system atrophy
      (MSA), progressive supranuclear palsy (PSP) and diffuse Lewy body disease (DLBD), as well as
      in patients with other basal ganglia disorders such as Huntington's disease (HD) and dopa
      responsive dystonia (DRD). The validated gene expression signatures will be utilised to
      develop a new test for diagnosis of idiopathic PD. Determine correlation between gene
      expression signatures and different stages of PD.

      Gene expression in presymptomatic and symptomatic patients with genetic forms of PD as well
      as patients in various stages of idiopathic PD will be analysed to identify gene expression
      signatures specific for various stages of the disease. It should be emphasised that since no
      clinical measures are present in presymptomatic genetic PD such molecular markers could serve
      as surrogate markers to monitor therapeutic efficacy of possible preventive treatments in PD.
      Determine correlations between gene expression signatures and morphological evidence of
      neurodegenerative process in PD brain as determined by neuroimaging. Gene expression
      signatures identified in blood samples will be correlated with changes in brain as detected
      by neuroimaging in PD patients. Such correlations of molecular and morphological markers of
      disease will facilitate the selection of blood markers in relation to disease progression.
      Moreover, molecular and morphological markers of disease progression could be utilised in
      combination for monitoring the effects of new neuroprotective therapies for PD. Develop
      standardised approaches to development and validation of haemogenomic biomarkers.

      This objective will be achieved by the special emphasis on careful clinical selection of
      patients, sufficient power regarding patient numbers, as well as extensive quality control
      and validation of the data. Develop new bioinformatic software tools for selection of genomic
      biomarkers using microarray data. The aim of the GENEPARK is to develop the theoretical
      foundations and to build the software tools for sample classification and selection of
      genomic biomarkers using microarray data. The established computational tools and novel
      methods developed within the GENEPARK will be applied to the patient data to study advantages
      and limitations of different methodologies.
    


Study Type

Observational




Condition

Parkinson Disease



Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

219

Start Date

October 2007

Completion Date

June 2012

Primary Completion Date

June 2012

Eligibility Criteria

        Inclusion Criteria:

          -  Diagnosis of Parkinson's disease

          -  Ability to understand the aim of the study

          -  Ability to sign the consent form

        Exclusion Criteria:

          -  Non ability to understand the aim of the study

          -  Non ability to sign the consent form

          -  To be over 18
      

Gender

All

Ages

18 Years - 90 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Borut Perterlin, MD, PhD, , 

Location Countries

Croatia

Location Countries

Croatia

Administrative Informations


NCT ID

NCT00465790

Organization ID

C06-56

Secondary IDs

2007-A00208-45

Responsible Party

Sponsor

Study Sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Collaborators

 European Union

Study Sponsor

Borut Perterlin, MD, PhD, Principal Investigator, University Medical Centre Ljubljana


Verification Date

December 2011